In addition, therapeutic targeting of this pathway may be relevant for the treatment of patients with SNPs in GIMAP5 linked to development of islet autoimmunity in T1D, SLE1–3, or asthma4. Here, GIMAP5 is linked to type 1 diabetes mellitus.